Table 3.

Quantification of pRab10^Thr73 phosphorylation levels by immunoblotting and targeted mass-spectrometry—one-way ANOVA followed by Tukey’s multiple comparisons where the LRRK2 dependent pRab10^Thr73 phosphorylation signal for each group was compared against all other groups as well as DMSO vs. MLi-2 treated samples per group including adjusted p value, mean difference and 95% confidence interval of difference

Tukey’s multiple comparisons test	Multiplex immunoblotting: normalized pRab10/total Rab10				Targeted mass-spectrometry: pRab10 occupancy (%)
	Summary	Adj. p value	Mean diff	95.00% CI of diff	Summary	Adj. p value	Mean diff	95.00% CI of diff
Control DMSO vs. iPD DMSO	ns	> 0.9999	0.06	− 0.4656 to 0.5851	ns	> 0.9999	− 0.0872	− 0.7808 to 0.6064
Control DMSO vs. G2019S DMSO	ns	> 0.9999	− 0.06	− 0.6140 to 0.5036	ns	0.7636	− 0.3795	− 1.117 to 0.3583
Control DMSO vs. R1441G DMSO	****	< 0.0001	− 3.61	− 4.177 to − 3.043	****	< 0.0001	− 5.073	− 5.822 to − 4.325
iPD DMSO vs. G2019S DMSO	ns	1.00	− 0.11	− 0.6987 to 0.4689	ns	0.9414	− 0.2923	− 1.063 to 0.4785
iPD DMSO vs. R1441G DMSO	****	< 0.0001	− 3.67	− 4.262 to − 3.078	****	< 0.0001	− 4.986	− 5.768 to − 4.205
G2019S DMSO vs. R1441G DMSO	****	< 0.0001	− 3.56	− 4.177 to − 2.933	****	< 0.0001	− 4.694	− 5.515 to − 3.873
Control (DMSO vs. MLi-2)	ns	> 0.9999	0.00	− 0.4975 to 0.4975	****	< 0.0001	1.224	0.5669 to 1.880
iPD (DMSO vs. MLi-2)	ns	> 0.9999	− 0.02	− 0.5675 to 0.5362	****	< 0.0001	1.361	0.6251 to 2.097
G2019S (DMSO vs. MLi-2)	ns	> 0.9999	− 0.03	− 0.6421 to 0.5861	****	< 0.0001	1.626	0.8158 to 2.437
R1441G (DMSO vs. MLi-2)	****	< 0.0001	3.62	2.994 to 4.252	****	< 0.0001	6.331	5.490 to 7.173

For the immunoblotting analysis it is important to note that results are normalized against the means of controls for the three separate sets of experiments as highlighted in the method section

ns non-significant